Sydal and Novo Nordisk Partner on Diabetes Medications in Algeria

Saidal Company signed an agreement with Novo Nordisk laboratories to produce innovative medications for the treatment of type 2 diabetes in Algeria, based on GLP-1 technology for patients suffering from overweight. This partnership will enable Algerian patients to benefit from modern treatments, contributing to better disease management and the prevention of cardiovascular and vascular complications.

Size: 120%Text Size

Notice: This Is an AI-Generated Summary

Display The Full Article